IPA-3 (PAK1 inhibitor) or OTSSP167 (MELK inhibitor) plus auranofin (PKCι inhibitor), a therapeutic option for EGFR mutant, KRAS mutant and squamous cell non-small cell lung cancer (NSCLC). | Publicación